Survival of patients with malignancy and on peritoneal dialysis: a multicenter cohort study in Thailand

Nintita Sripaiboonkij Thokanit ¹, Jirayut Janma ², Watanyu Parapiboon³, Pornpen Sangthawan ⁴, Siribha Changsirikulchai ²

Ramathibodi Comprehensive Cancer Center, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Thailand ¹,
Renal Division, Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Thailand ²,
Renal Division, Department of Medicine, MaharatNakornratchasima Hospital, Ministry of Public Health, Thailand ³,
Renal Division, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Thailand ⁴

Purpose: Survival of patients with cancer and on peritoneal dialysis (PD) in Thailand has not been reported. This study aims to investigate prevalence and survival of patient with malignancy and on PD.

Method: A retrospective cohort study from data registry on Database of Peritoneal dialysis in EXcel (DPEX) during 2008 to 2018 was analyzed. There were 242 cancer patients from 21,885 end stage renal disease (ESRD) patients on PD. All cases of patients were censored at the time of death or December 31, 2018. The diagnosis of cancer was ascertained according to the International Classification of Diseases for Oncology: Third Edition

Result: The percentage of patients with cancer and on PD was 1.1%. The sites of cancer were lung (12.8%), colorectal (12.4%), multiple myeloma (8.7%), liver (7.4%) and breast cancer (7.0%). The mean (SD) age at starting PD was 57.3 (15.8) years and 56.6% in male. Median duration time from initiated PD to censor was 16.3 months (0.03-101.97). During a 461.8 person year of 242 patients, 51.2% patients died. The overall survival rate at 1, 3, 5 years were 79.2%, 46.4% and 26.3%, respectively and median survival time was 2.6 years. Survival rates of PD patient with cancer and having historical of diabetes were low. The 1, 3 and 5 years
patient survival were 82.0%, 39.0% and 13.0%, respectively. Site of cancer with poor survival were liver, lung and female cancer.

Conclusion: One year survival of patients with cancer and on PD was compatible with results published in PDI 2018.